Abstract

The Pathology Core has been developed in conjunction with the clinical and basic sciences projects. The procurement of tissue, analysis of samples and staging of the excised specimens has been in operation for several years and is conducted within the Division of Surgical Pathology. The goal of this core is to assure a complete diagnostic evaluation of surgical specimens. Paraffin blocks and snap frozen normal and tumor tissues of rectal adenocarcinomas and recurrent colon cancers will be used for these purposes. Gross and microscopic examination of mouse gastrointestinal tumors will also be performed. In addition to pathological examination, the Pathology Core will perform immunohistochemical analysis of tumor samples with primary antibody stains that include proliferation and prognostic markers (Ki-67, p53, Topoisomerase II, p27 and p21/WAF1/CIP1, Bcl-2 and Fhit) and markers of mismatch repair deficiencies (hMSH2, hMLH1 and Hmsh6). The presence and distribution of the PLA2G2A (secretory non-pancreatic phospholipase 2) will be investigated in normal human colonic mucosa and in colorectal tumors. Immunohistochemical stains will be interpreted in conjunction with the results form the basic research projects (Projects 2 and 3) and the Molecular Genetics Core. The Pathology Core will handle and distribute all tissues, prepare DNA (and RNA if sufficient tissue is available) from microdissected tumor/normal samples, and document/report its finding for correlation of marker expression with patient's response to therapy and outcome.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA072027-03
Application #
6651271
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost

  Institution

Name
Thomas Jefferson University
Department
Type
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107

  Publications

Nnadi, Stephanie C; Watson, Rayneisha; Innocent, Julie et al. (2012) Identification of five novel modifier loci of Apc(Min) harbored in the BXH14 recombinant inbred strain. Carcinogenesis 33:1589-97
Sevignani, Cinzia; Calin, George A; Siracusa, Linda D et al. (2006) Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 17:189-202
Markova, Marina; Koratkar, Revati A; Silverman, Karen A et al. (2005) Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis. Oncogene 24:6450-8
Koratkar, Revati; Silverman, Karen A; Pequignot, Ed et al. (2004) Analysis of reciprocal congenic lines reveals the C3H/HeJ genome to be highly resistant to ApcMin intestinal tumorigenesis. Genomics 84:844-52
Charara, Mona; Edmonston, Tina Bocker; Burkholder, Susan et al. (2004) Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24:3161-7
Boman, Bruce M; Walters, Rhonda; Fields, Jeremy Z et al. (2004) Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol 165:1489-98
Ghiselli, Giancarlo; Coffee, Nefeteria; Munnery, Christine E et al. (2003) The cohesin SMC3 is a target the for beta-catenin/TCF4 transactivation pathway. J Biol Chem 278:20259-67
Silverman, Karen A; Koratkar, Revati A; Siracusa, Linda D et al. (2003) Exclusion of Madh2, Madh4, and Madh7 as candidates for the modifier of Min 2 (Mom2) locus. Mamm Genome 14:119-29
Cutler, N Shane; Graves-Deal, Ramona; LaFleur, Bonnie J et al. (2003) Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63:1748-51
Stein, David E; Mahmoud, Najjia N; Anne, Pramila Rani et al. (2003) Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 46:448-53

Showing the most recent 10 out of 15 publications